Lenvima

Adult Dosing .

Dosage forms:  CAP: 4 mg; CAP (8 mg dose pack): 4 mg x60; CAP (12 mg dose pack): 4 mg x90; CAP (14 mg dose pack): 4 mg x30 and 10 mg x30; CAP (18 mg dose pack): 4 mg x60 and 10 mg x30; CAP (20 mg dose pack): 10 mg x60; CAP (24 mg dose pack): 4 mg x30 and 10 mg x60

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments; D/C >1wk before elective surgery, restart >2wk after major surgery when wound fully healed

differentiated thyroid CA, locally recurrent or metastatic

[24 mg PO qd]

Info: for patients w/ progressive and radioactive iodine-refractory dz; do not open cap, but may dissolve cap in water or apple juice

renal cell CA, advanced

[first-line tx, combo w/ pembrolizumab]

Dose: 20 mg PO qd w/ pembrolizumab for up to 2y, then may give as monotherapy; Info: do not open cap, but may dissolve cap in water or apple juice

[previously treated dz, combo w/ everolimus]

Dose: 18 mg PO qd; Info: for patients who have received prior antiangiogenic tx; do not open cap, but may dissolve cap in water or apple juice

hepatocellular CA, unresectable

[first-line tx, <60 kg]

Dose: 8 mg PO qd; Info: dose based on ABW; do not open cap, but may dissolve cap in water or apple juice

[first-line tx, >60 kg]

Dose: 12 mg PO qd; Info: dose based on ABW; do not open cap, but may dissolve cap in water or apple juice

endometrial carcinoma, advanced

[20 mg PO qd]

Info: for patients w/ mismatch repair proficient or non-microsatellite instability-high progressive dz not eligible for curative surgery or XRT; use w/ pembrolizumab; do not open cap, but may dissolve cap in water or apple juice

renal dosing

[differentiated thyroid CA, locally recurrent or metastatic]

CrCl 15-29: 14 mg qd; CrCl <15: not defined

HD/PD: not defined

[renal cell CA, advanced]

CrCl 15-29: 10 mg qd; CrCl <15: not defined

HD/PD: not defined

[hepatocellular CA, unresectable]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

[endometrial carcinoma, advanced]

CrCl 15-29: 10 mg qd; CrCl <15: not defined

HD/PD: not defined

hepatic dosing

[differentiated thyroid CA, locally recurrent or metastatic]

Child-Pugh Class C: 14 mg qd

[renal cell CA, advanced]

Child-Pugh Class C: 10 mg qd

[hepatocellular CA, unresectable]

Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: not defined

[endometrial carcinoma, advanced]

Child-Pugh Class C: 10 mg qd

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.